Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.451

-4.8%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (43)	5/4/2007 6:19:12 PM
From: DewDiligence_on_SI	Read Replies (1) of 66

Treatment of chronic HBV is a rapidly evolving arena. I see no reason why $500M in 2010 for Tyzeka has been ruled out yet. At this point, Baraclude and Tyzeka are clearly the best drugs and it’s only a matter of time until they supplant Lamivudine and Hepsera. (Hepsera may do OK as a second agent if N+N combination therapy becomes the SoC, but that’s a separate issue.)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next